Illumina (NASDAQ:ILMN) has outperformed the market over the past 20 years by 4.32% on an annualized

ILMN's sequencing growth, oncology momentum and multiomics expansion support its outlook, though cos

On August 19, 2026, Merck (NYSE:MRK | MRK Price Prediction) and Moderna (NASDAQ:MRNA) announced posi

Biondo Investment Advisors LLC bought a new stake in shares of Illumina, Inc. (NASDAQ: ILMN) in the

Allworth Financial LP acquired a new position in Illumina, Inc. (NASDAQ: ILMN) in the second quarter

Illumina delivered strong Q2 2026 results, beating on EPS and revenue, and raised full-year guidance

Long-end Treasury yields snapped back toward 20-month highs; Walmart posted its worst session in fou

Dow Jones down 300 points, Deere & Co shares up 7.9% after beating earnings expectations. SCTX,

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the

Empowered Funds LLC raised its stake in Illumina, Inc. (NASDAQ: ILMN) by 104.2% during the first qua

Illumina (ILMN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further t

Illumina (NASDAQ:ILMN) has outperformed the market over the past 20 years by 3.84% on an annualized

Canaccord Genuity analyst Kyle Mikson maintains Illumina (NASDAQ:ILMN) with a Hold and raises the

Citigroup analyst Joanne Wuensch maintains Illumina (NASDAQ:ILMN) with a Sell and raises the pric

Piper Sandler analyst David Westenberg reiterates Illumina (NASDAQ:ILMN) with a Overweight and ra

Illumina (ILMN) is at a 52-week high, but can investors hope for more gains in the future? We take a

RBC Capital analyst Dan Leonard maintains Illumina (NASDAQ:ILMN) with a Outperform and raises the

JP Morgan analyst Casey Woodring maintains Illumina (NASDAQ:ILMN) with a Overweight and raises th

TD Cowen analyst Dan Brennan maintains Illumina (NASDAQ:ILMN) with a Hold and raises the price ta

Guggenheim analyst Subbu Nambi maintains Illumina (NASDAQ:ILMN) with a Buy and raises the price t

Stifel analyst Daniel Arias maintains Illumina (NASDAQ:ILMN) with a Buy and raises the price targ

Barclays analyst Luke Sergott maintains Illumina (NASDAQ:ILMN) with a Underweight and raises the

The headline numbers for Illumina (ILMN) give insight into how the company performed in the quarter

Illumina, Inc. (ILMN) Q2 2026 Earnings Call Transcript

Illumina (ILMN) came out with quarterly earnings of $1.31 per share, beating the Zacks Consensus Est

Illumina (NASDAQ:ILMN) raises FY2026 Adj EPS guidance from $5.15-$5.30 to $5.30-$5.40 vs $5.23 analy

SAN DIEGO, July 30, 2026 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company")

Get a deeper insight into the potential performance of Illumina (ILMN) for the quarter ended June 20

Sale of Mass Cytometry Business to Multiplex Bio Ensures Full Continuity of CyTOF and Hyperion Produ

Tema's new Healthcare AI ETF (HLTH), targets AI-powered drug discovery, diagnostics, robotics an

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both

CHICAGO--(BUSINESS WIRE)---- $ILMN #AI--Fishbone Advisors, a capital markets intelligence firm, toda

Amova Asset Management Americas Inc. trimmed its position in Illumina, Inc. (NASDAQ: ILMN) by 18.6%

Leerink Partners analyst Puneet Souda maintains Illumina (NASDAQ:ILMN) with a Outperform and rais

Canaccord Genuity analyst Kyle Mikson maintains Illumina (NASDAQ:ILMN) with a Hold and raises the

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Evercore ISI Group analyst Vijay Kumar maintains Illumina (NASDAQ:ILMN) with a Outperform and rai

Piper Sandler analyst David Westenberg maintains Illumina (NASDAQ:ILMN) with a Overweight and rai

Guggenheim analyst Subbu Nambi maintains Illumina (NASDAQ:ILMN) with a Buy and raises the price t

Bernstein analyst Eve Burstein reinstates Illumina (NASDAQ:ILMN) with a Market Perform and announ

Barclays analyst Luke Sergott maintains Illumina (NASDAQ:ILMN) with a Underweight and raises the

JP Morgan analyst Casey Woodring upgrades Illumina (NASDAQ:ILMN) from Neutral to Overweight and r

StrataMap Spatial meets the growing demand for scalable spatial biology studies from research and bi

Integrated, push-button oncology research workflows give customers a simplified path from library pr

Guggenheim analyst Subbu Nambi maintains Illumina (NASDAQ:ILMN) with a Buy and raises the price t

As a distributed kit, it will enable more labs to adopt MRD detection for clinical research. Now in

RBC Capital analyst Dan Leonard reinstates Illumina (NASDAQ:ILMN) with a Outperform and announces

President Donald Trump arrives in China for a high-stakes meeting with President Xi Jinping, bringin